Pericarditis News and Research

RSS

Pericarditis is defined as the state of inflammation or infection of the pericardium, the membranous sac that encloses the heart. The cause and severity of pericarditis determines the type of treatment appropriate for this condition.

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Now, in new research, the everyday painkiller aspirin will be evaluated as a potential treatment for COVID-19 in one of the United Kingdom’s most significant trials, aiming to evaluate whether it can reduce the risk of blood clots in infected people.

9 Nov 2020

Study indicates the relationship between SARS-CoV-2 viral infection and diabetes

It has recently been described that infection by some enteroviruses - a genus of viruses that commonly cause diseases of varying severity - could potentially trigger diabetes, although its direct effect 'in vivo' as well as its mechanism of action at the molecular level were unknown.

21 Oct 2020

Severe and fatal COVID-19 is rare in children

Now, a new study by researchers at the Universities of Edinburgh and Liverpool, Imperial College London, and the Royal Hospital for Children, Glasgow in the United Kingdom has shown that children and teenagers are less likely than adults to develop severe COVID-19 or die from the disease.

30 Aug 2020

Study shows how picornaviruses infect the host cell

Picornaviruses is a family of viruses that can cause a number of different diseases, including polio, meningitis, and in rare cases myocarditis, encephalitis, and paralysis.

13 Aug 2020

COVID-19: What the illness looks like

With increasing information about COVID-19 disease gathered first-hand, a more accurate picture of the clinical features is coming together.

2 Apr 2020

Rheumatoid arthritis linked to other diseases, finds new study

A study found that risk of developing rheumatoid arthritis is higher in people with certain diseases.

21 Nov 2019

Cancer survivors could be at greater risk of cardiovascular diseases

Over the last few decades, medical progress has led to the survival of many more people with cancer. However, a new study published in The Lancet shows that this cohort has a higher risk of cardiovascular disease (CVD) than controls without cancer, due to a number of reasons.

21 Aug 2019

Study shows potential culprit behind Lupus

A team of researchers at the Emory University School of Medicine show that patients with SLE or lupus, have abnormal activation of B cells, which is part of the body’s immune system

8 Jul 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Case study shows how intravascular ultrasound imaging helps detect acute aortic syndrome

In the current issue of Cardiovascular Innovations and Applications (Volume 2, Number 4, 2018, pp 447-449(3); DOI: https://doi.org/10.15212/CVIA.2017.0028, Niya Mileva, Medical University of Sofia, Sofia, Bulgaria and other researchers from Poland and Italy present a case study of misdiagnosed aortic intramural hematoma and the role of intravascular ultrasound imaging in detection of acute aortic syndrome.

19 Apr 2018

Pericarditis News and Research

Further Reading

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Study indicates the relationship between SARS-CoV-2 viral infection and diabetes

Severe and fatal COVID-19 is rare in children

Study shows how picornaviruses infect the host cell

COVID-19: What the illness looks like

Rheumatoid arthritis linked to other diseases, finds new study

Cancer survivors could be at greater risk of cardiovascular diseases

Study shows potential culprit behind Lupus

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Celgene to share new and updated data around novel hematological therapies

Case study shows how intravascular ultrasound imaging helps detect acute aortic syndrome

Research reveals how bacteria prepare sticky adhesion protein

Review assesses safety, effectiveness of corticosteroids for treating TB pericarditis

Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News